Myriad Genetics, Inc. (MYGN)
Market Cap | 682.99M |
Revenue (ttm) | 837.60M |
Net Income (ttm) | -127.30M |
Shares Out | 92.17M |
EPS (ttm) | -1.41 |
PE Ratio | n/a |
Forward PE | 94.13 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,218,000 |
Open | 7.16 |
Previous Close | 7.20 |
Day's Range | 7.11 - 7.55 |
52-Week Range | 7.16 - 29.30 |
Beta | 1.87 |
Analysts | Hold |
Price Target | 20.17 (+172.02%) |
Earnings Date | May 6, 2025 |
About MYGN
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and meta... [Read more]
Financial Performance
In 2024, Myriad Genetics's revenue was $837.60 million, an increase of 11.21% compared to the previous year's $753.20 million. Losses were -$127.30 million, -51.65% less than in 2023.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is $20.17, which is an increase of 172.02% from the latest price.
News

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
More than half say genetic testing for mental health medications could reduce concerns More than half say genetic testing for mental health medications could reduce concerns

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD Podium presentation showcases the clinical application of Precise™ MRD

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical ...

Myriad Genetics Announces Inducement Awards
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the ...

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donn...

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics'...

Myriad Genetics, Inc. (MYGN) Q4 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President an...

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71....

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial i...

Myriad Genetics Included in Forbes America's Best Employers 2025 List
SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of Amer...

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announ...

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent an...

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital patho...

Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at t...

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensi...

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal).

Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights
NEW YORK--(BUSINESS WIRE)--Diligent, a leading GRC SaaS company, today announced it is collaborating with S&P Global's Market Intelligence division to launch Diligent Market Insights Reporting. Powere...

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally renow...

UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genet...

Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present ...

Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Respon...

Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.

Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealth...

Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio ...